Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Lee

Sports Medicine Burbank, CA Medical Doctor

NPI 1053512558 CMS profile 1105302

191 S Buena Vista St, Suite 470, Burbank, CA 91505

Open in the dashboard

General payments

$86,009

85 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Lee of Burbank, CA is reported in the CMS Open Payments database as having received $86,009 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,804 9
2024 General $22,390 18
2023 General $3,576 3
2022 General $27,141 19
2021 General $12,747 11
2020 General $9,332 15
2019 General $6,018 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Lee
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Christopher Lee were reported at $4,804. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Christopher Lee Sports Medicine median Middle half National median
2019 $6,018 $1,176 $199–$4,249 $163
2020 $9,332 $708 $96–$2,890 $114
2021 $12,747 $1,213 $152–$3,994 $132
2022 $27,141 $1,230 $159–$3,998 $149
2023 $3,576 $584 $146–$2,836 $160
2024 $22,390 $628 $163–$3,168 $164
2025 $4,804 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $52,902 25 payments
  2. Linvatec Corporation $19,797 23 payments
  3. Vericel Corporation $4,857 10 payments
  4. DePuy Synthes Products, Inc. $3,590 2 payments
  5. Synthes USA Products LLC $1,447 6 payments
  6. Micromed Inc $1,431 1 payment
  7. Smith+Nephew, Inc. $843 5 payments
  8. Musculoskeletal Transplant Foundation Inc. $446 2 payments
  9. Stryker Corporation $382 5 payments
  10. Anika Therapeutics, Inc. $160 3 payments
  11. Other $154 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $68,782 19 payments
  2. Travel and Lodging $5,480 25 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $4,200 2 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $3,600 1 payment
  5. Food and Beverage $2,515 37 payments
  6. Education $1,431 1 payment
Products named General payments · program years 2019–2025
  1. TRUMATCH $46,880 12 payments
  2. GLOBAL $46,880 12 payments
  3. LINVATEC SHOULDER ARTHROSCOPY $14,187 10 payments
  4. LCP $5,984 3 payments
  5. MACI $4,828 8 payments
  6. BIOBRACE 23MM $3,570 3 payments
  7. LCP PLATES & SCREWS $2,029 2 payments
  8. LINVATEC KNEE PRESERVATION SYSTEM $1,647 3 payments
  9. BIOLOX DELTA $885 3 payments
  10. NAVIO $479 1 payment
  11. Other $2,568 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

428

Median for Orthopedic Surgery: 203

Drug cost

$8,571

Median for Orthopedic Surgery: $1,433

Branded share of claims

18.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 22 $5,698
Cephalexin Generic 77 $990
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 33 $498
Meloxicam Generic 163 $475
Diclofenac Sodium Generic 46 $327
Celecoxib Generic 19 $278
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $126
Methylprednisolone Generic 16 $85
Tramadol Hcl Generic 29 $48
Ondansetron Odt Ondansetron Brand 12 $47

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$162,060

Of which drugs: $558

Medicare patients

407

Average age 73

Services billed

1,703

255 women, 152 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 65%
Diabetes 25%
Ischemic heart disease 22%
Depression 20%
Osteoporosis 20%
Cancer 15%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 29 84 $442

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record